Skip to main content

Advertisement

SpringerLink
Log in

Managing the Risks of ADHD Treatments

  • Attention-Deficit Disorder (A Rostain, Section Editor)
  • Published:
Current Psychiatry Reports Aims and scope Submit manuscript

Abstract

Pharmacotherapy of attention deficit-hyperactivity disorder (ADHD) is a well-established and effective treatment modality. However, ADHD medications are not without side effects. Understanding the prevalence of adverse events and effective management of risks associated with stimulants and other medications used to treat ADHD is central to broad applicability and effective treatment. This review discusses the literature on the prevalence of adverse events and management strategies employed. We searched online MEDLINE/PubMed and Cochrane databases for articles using several keywords relating to adverse events associated with ADHD medication management. We discuss the relevant data on the significance and prevalence of side effects and adverse events, highlight recent updates in the field, and suggest approaches to clinical management.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.

    Article  PubMed  Google Scholar 

  2. Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99. A notable review in that it focused on long-term outcomes in which ADHD treatments were shown to reduce the negative impact of ADHD.

    Article  PubMed  PubMed Central  Google Scholar 

  3. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch. Gen. Psychiatry. 1999;56:1073–86.

  4. Döpfner M, Ise E, Wolff Metternich-Kaizman T, Schürmann S, Rademacher C, Breuer D. Adaptive multimodal treatment for children with attention-deficit/hyperactivity disorder: an 18 month follow-up. Child Psychiatry Hum. Dev. 2014. An 18-month follow-up to the Cologne Adaptive Multimodal Treatment (CAMT) study showing that the initial advantage of combined treatment over behavioral treatment was no longer evident at 18 months.

  5. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921.

    Article  PubMed  Google Scholar 

  6. Partridge B, Lucke J, Hall W. Over-diagnosed and over-treated: a survey of Australian public attitudes towards the acceptability of drug treatment for depression and ADHD. BMC Psychiatry. 2014;14:74.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Findling RL, Biederman J, Wilens TE, Spencer TJ, McGough JJ, Lopez FA, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147:348–54.

    Article  PubMed  CAS  Google Scholar 

  8. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011;50:978–90. Showed a small subset of children and adolescents may have a greater increase in pulse or blood pressure. Found it to be extremely rare for a child or adolescent to have a serious cardiovascular event during treatment with the risk being similar to that in people not receiving treatment.

    Article  PubMed  Google Scholar 

  9. Rapport MD, Moffitt C. Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects. Clin Psychol Rev. 2002;22:1107–31.

    Article  PubMed  Google Scholar 

  10. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006;21:92–5.

    Article  PubMed  Google Scholar 

  11. Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008;47:189–98.

    Article  PubMed  Google Scholar 

  12. Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51(1):74–85.e2. A notable paper in that it looks at the safety of combining psychostimulants and alpha-2-agonists for the treatment of ADHD. Combination treatment was shown to be effective, and no new safety concerns were presented.

    Article  PubMed  Google Scholar 

  13. Roesch B, Corcoran M, Haffey M, Stevenson A, Wang P, Purkayastha J, et al. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Drugs R D. 2013;13:53–61. Open-label study of adults comparin Intuniv, Concerta, or combination treatment. No significant drug-drug interactions were found.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  14. Olfson M, Huang C, Gerhard T, Winterstein AG, Crystal S, Allison PD, et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:147–56. Cohort analysis showing cardiovascular events were rare and not associated with stimulant use, suggesting the safety of ADHD medication treatment in young people without known risk factors.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Habel LA, Cooper WO, Sox CM, Chan KA, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306:2673–83.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  16. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896–904. Large cohort study showing no evidence that current use of ADHD drugs was associated with increased risk of cardiovascular events.

    Article  PubMed  CAS  Google Scholar 

  17. Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127:1102–10. Cohort study that looked at stimulants as well as atomoxetine showing the rate of cardiovascular events to be very low and not significantly higher than in control subjects.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Winterstein AG, Gerhard T, Kubilis P, Saidi A, Linden S, Crystal S, et al. Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study. BMJ. 2012;345:e4627.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Dalsgaard S, Kvist AP, Leckman JF, Nielsen HS, Simonsen M. Cardiovascular safety of stimulants in children with attention-deficit/hyperactivity disorder: A nationwide prospective cohort study. J. Child Adolesc. Psychopharmacol. 2014. Cohort study that looked at long-term effects of stimulants. Notable for the longer observation period.

  20. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J. Dev. Behav. Pediatr. 2008;29:335.

  21. Perrin JM, Friedman RA, Knilans TK. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122:451–3.

    Article  PubMed  Google Scholar 

  22. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Cardiac Congenital Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117:2407–23.

    Article  PubMed  Google Scholar 

  23. Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54:227–46. A notable review on medication management of ADHD. Provides expert consensus of the members of the European ADHD Guidelines Group.

    Article  PubMed  Google Scholar 

  24. Schachter HM, Pham B, King J, Langford S, Moher D. How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ. 2001;165:1475–88.

    PubMed  CAS  PubMed Central  Google Scholar 

  25. Cheng JYW, Chen RYL, Ko JSN, Ng EML. Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and meta-regression analysis. Psychopharmacol (Berl). 2007;194:197–209.

    Article  CAS  Google Scholar 

  26. Wang Y, Zheng Y, Du Y, Song DH, Shin Y-J, Cho SC, et al. Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: a randomized, double-blind comparison trial. Aust N Z J Psychiatry. 2007;41:222–30.

    Article  PubMed  CAS  Google Scholar 

  27. Biederman J, Spencer TJ, Monuteaux MC, Faraone SV. A naturalistic 10-year prospective study of height and weight in children with attention-deficit hyperactivity disorder grown up: sex and treatment effects. J Pediatr. 2010;157:635–40. 640.e1.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Faraone SV, Biederman J, Morley CP, Spencer TJ. Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:994–1009.

    PubMed  Google Scholar 

  29. Daviss WB, Scott J. A chart review of cyproheptadine for stimulant-induced weight loss. J Child Adolesc Psychopharmacol. 2004;14:65–73.

    Article  PubMed  Google Scholar 

  30. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:E105.

    Article  PubMed  CAS  Google Scholar 

  31. Konofal E, Lecendreux M, Cortese S. Sleep and ADHD. Sleep Med. 2010;11:652–8.

    Article  PubMed  Google Scholar 

  32. Tjon Pian Gi CV, Broeren JPA, Starreveld JS, Versteegh FGA. Melatonin for treatment of sleeping disorders in children with attention deficit/hyperactivity disorder: a preliminary open label study. Eur J Pediatr. 2003;162:554–5.

    Article  PubMed  Google Scholar 

  33. James SP, Mendelson WB. The use of trazodone as a hypnotic: a critical review. J Clin Psychiatry. 2004;65:752–5.

    Article  PubMed  CAS  Google Scholar 

  34. Cortese S, Konofal E, Lecendreux M, Arnulf I, Mouren M-C, Darra F, et al. Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep. 2005;28:1007–13.

    PubMed  Google Scholar 

  35. Kaplan G, Newcorn JH. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatr Clin North Am. 2011;58:99–120. xi.

    Article  PubMed  Google Scholar 

  36. Roessner V, Robatzek M, Knapp G, Banaschewski T, Rothenberger A. First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol. 2006;48:616–21.

    Article  PubMed  Google Scholar 

  37. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry. 2009;48:884–93.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Charach A, Yeung E, Climans T, Lillie E. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry. 2011;50:9–21.

    Article  PubMed  Google Scholar 

  39. Lee SS, Humphreys KL, Flory K, Liu R, Glass K. Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review. Clin Psychol Rev. 2011;31:328–41.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Molina BSG, Hinshaw SP, Eugene Arnold L, Swanson JM, Pelham WE, Hechtman L, et al. Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication. J Am Acad Child Adolesc Psychiatry. 2013;52:250–63. Notable follow-up to the Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder looking at the relationship between medication and subsequent substance use disorder. Medication for ADHD did not impact future substance use or substance use disorders.

    Article  PubMed  PubMed Central  Google Scholar 

  41. APA. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.

  42. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111:179–85.

    Article  PubMed  Google Scholar 

  43. Groenman AP, Oosterlaan J, Rommelse NNJ, Franke B, Greven CU, Hoekstra PJ, et al. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder. Br J Psychiatry. 2013;203:112–9. Study in which stimulant use, especially at an earlier age, seemed to reduce the risk of future substance use disorders.

    Article  PubMed  Google Scholar 

  44. Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry. 2008;47:21–31.

    Article  PubMed  Google Scholar 

  45. McCabe SE, Knight JR, Teter CJ, Wechsler H. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction. 2005;100:96–106.

    Article  PubMed  Google Scholar 

  46. Lakić A. Depressive symptoms as a side effect of the sustained release form of methylphenidate in a 7-year-old boy with attention-deficit hyperactivity disorder. Vojnosanit Pregl. 2012;69:201–4.

    Article  PubMed  Google Scholar 

  47. Wilens TE, Biederman J. The stimulants. Psychiatr Clin North Am. 1992;15:191–222.

    PubMed  CAS  Google Scholar 

  48. Barkley RA. The effects of methylphenidate on the interactions of preschool ADHD children with their mothers. J Am Acad Child Adolesc Psychiatry Elsevier. 1988;27:336–41.

    Article  CAS  Google Scholar 

  49. Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, et al. Safety and tolerability of methylphenidate in preschool children with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45:1294–303.

    Article  PubMed  Google Scholar 

  50. Childress AC, Arnold V, Adeyi B, Dirks B, Babcock T, Scheckner B, et al. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial. J Atten Disord. 2014;18:123–32. A notable outpatient clinical trial that found lisdexamfetamine dimesylate improved both ADHD symptoms and emotional lability.

    Article  PubMed  Google Scholar 

  51. Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics. 2009;123:611–6.

    Article  PubMed  Google Scholar 

  52. Goldsmith M, Singh M, Chang K. Antidepressants and psychostimulants in pediatric populations: is there an association with mania? Paediatr Drugs. 2011;13:225–43.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Davis SM, Katusic SK, Barbaresi WJ, Killian J, Weaver AL, Ottman R, et al. Epilepsy in children with attention-deficit/hyperactivity disorder. Pediatr Neurol. 2010;42:325–30.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Fosi T, Lax-Pericall MT, Scott RC, Neville BG, Aylett SE. Methylphenidate treatment of attention deficit hyperactivity disorder in young people with learning disability and difficult-to-treat epilepsy: evidence of clinical benefit. Epilepsia. 2013;54:2071–81.

    Article  PubMed  CAS  Google Scholar 

  55. Santos K, Palmini A, Radziuk AL, Rotert R, Bastos F, Booij L, et al. The impact of methylphenidate on seizure frequency and severity in children with attention-deficit-hyperactivity disorder and difficult-to-treat epilepsies. Dev Med Child Neurol. 2013;55:654–60. Pilot study evaluating safety and efficacy of methylphenidate in a population with difficult-to-treat epilepsy.

    Article  PubMed  Google Scholar 

  56. Kelly BD, Lundon DJ, McGuinness D, Brady CM. Methylphenidate-induced erections in a prepubertal child. J Pediatr Urol. 2013;9:e1–2.

    Article  PubMed  CAS  Google Scholar 

  57. Cakin-Memik N, Yildiz O, Sişmanlar SG, Karakaya I, Ağaoğlu B. Priapism associated with methylphenidate: a case report. Turk J Pediatr. 2012;52:430–4.

    Google Scholar 

  58. Husár M, Zerhau P. Priapism in childhood—case report of 14-year-old boy. Rozhl Chir. 2006;85:329–30.

    PubMed  Google Scholar 

  59. Schwartz RH, Rushton HG. Stuttering priapism associated with withdrawal from sustained-release methylphenidate. J Pediatr. 2004;144:675–6.

    Article  PubMed  Google Scholar 

  60. Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J Psychopharmacol. 2014;28:204–11.

    Article  PubMed  Google Scholar 

  61. Agosti V, Chen Y, Levin FR. Does attention deficit hyperactivity disorder increase the risk of suicide attempts? J Affect Disord. 2011;133:595–9.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Benjamin N. Schneider and Michael Enenbach declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Division of Child & Adolescent Psychiatry, UCLA Semel Institute for Neuroscience & Human Behavior, 760 Westwood Plaza, Suite 68-251A, Los Angeles, CA, 90024, USA

    Benjamin N. Schneider

  2. Division of Child & Adolescent Psychiatry, UCLA Semel Institute for Neuroscience & Human Behavior, 300 UCLA Medical Plaza, Suite 1227, Los Angeles, CA, 90095, USA

    Michael Enenbach

Authors
  1. Benjamin N. Schneider
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Enenbach
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Benjamin N. Schneider or Michael Enenbach.

Additional information

This article is part of the Topical Collection on Attention-Deficit Disorder

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schneider, B.N., Enenbach, M. Managing the Risks of ADHD Treatments. Curr Psychiatry Rep 16, 479 (2014). https://doi.org/10.1007/s11920-014-0479-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11920-014-0479-3

Keywords

Search

Navigation